Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807)

We carried out a phase I/II trial of adding 2-weekly docetaxel to cisplatin plus fluorouracil (CF) therapy (2-weekly DCF regimen) in esophageal cancer patients to investigate its safety and antimetastatic activity. Patients received 2-weekly docetaxel (30 mg/m(2) [dose level (DL)1] or 40 mg/m(2) [DL...

Descripción completa

Detalles Bibliográficos
Autores principales: Hironaka, Shuichi, Tsubosa, Yasuhiro, Mizusawa, Junki, Kii, Takayuki, Kato, Ken, Tsushima, Takahiro, Chin, Keisho, Tomori, Akihisa, Okuno, Tatsuya, Taniki, Toshikatsu, Ura, Takashi, Matsushita, Hisayuki, Kojima, Takashi, Doki, Yuichiro, Kusaba, Hitoshi, Fujitani, Kazumasa, Taira, Koichi, Seki, Shiko, Nakamura, Tsutomu, Kitagawa, Yuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462397/
https://www.ncbi.nlm.nih.gov/pubmed/25041052
http://dx.doi.org/10.1111/cas.12486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462397/
https://www.ncbi.nlm.nih.gov/pubmed/25041052
http://dx.doi.org/10.1111/cas.12486

Ejemplares similares